Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA). Our primary focus lies in addressing unmet medical needs in rare diseases by using precision medicine approaches. We are working on several disease areas that include HDV infection, chylomicronemia syndrome (patients with extremely high triglyceride levels and suffering from frequent pancreatitis), as well as rare kidney diseases such as IgA nephropathy. We also have our own clinical trial unit specialized for clinical phase 2 studies. All Ribocure staff are located in the GoCo Clinic building, GoCo Health Innovation City in Mölndal, Sweden.

Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease
Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals

